Download PDF
Semin Liver Dis 2023; 43(04): 383-401
DOI: 10.1055/s-0043-1776127
Review Article

Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

Xinpu Han‡   *
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
,
Qianhui Sun‡   *
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
,
Manman Xu‡   *
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
,
Guanghui Zhu
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
,
Ruike Gao
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
,
Baoyi Ni
2   Department of Oncology, First Hospital of Heilongjiang University of Chinese Medicine, Harbin, People's Republic of China
,
Jie Li
1   Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, People's Republic of China
› Author Affiliations Funding This research was supported by the National Natural Science Foundation of China (NSFC-81774289; NSFC-82074402; and NSFC-82204922).
› Further Information
    Permissions and Reprints


Abstract

Immune checkpoint inhibitors (ICIs) have emerged as effective therapeutics for multiple cancers. Nevertheless, as immunotherapeutic approaches are being extensively utilized, substantial hurdles have arisen for clinicians. These include countering ICIs resistance and ensuring precise efficacy assessments of these drugs, especially in the context of hepatocellular carcinoma (HCC). This review attempts to offer a holistic overview of the latest insights into the ICIs resistance mechanisms in HCC, the molecular underpinnings, and immune response. The intent is to inspire the development of efficacious combination strategies. This review also examines the unconventional response patterns, namely pseudoprogression (PsP) and hyperprogression (HPD). The prompt and rigorous evaluation of these treatment efficacies has emerged as a crucial imperative. Multiple clinical, radiological, and biomarker tests have been advanced to meticulously assess tumor response. Despite progress, precise mechanisms of action and predictive biomarkers remain elusive. This necessitates further investigation through prospective cohort studies in the impending future.

Keywords

immunotherapy - pseudoprogression - hyperprogression - resistance - hepatocellular carcinoma

Author Contributions

Xinpu Han, Qianhui Sun, Manman Xu contributed to the investigation, methodology, data curation, and writing, review, and editing. Guanghui Zhu, Ruike Gao, and Baoyi Ni contributed to software, data curation. Jie Li contributed to methodology, supervision, and writing, review, and editing, resources, and funding acquisition.


* These authors contributed equally to this work and retain the first authorship.




Publication History

Article published online:
06 November 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • Reference

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    Google Scholar
  • 2 Llovet JM, Castet F, Heikenwalder M. et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2022; 19 (03) 151-172
    CrossrefPubMedGoogle Scholar
  • 3 Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380 (15) 1450-1462
    CrossrefPubMedGoogle Scholar
  • 4 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
    CrossrefPubMedGoogle Scholar
  • 5 Rinaldi L, Guarino M, Perrella A. et al. Role of liver stiffness measurement in predicting HCC occurrence in direct-acting antivirals setting: a real-life experience. Dig Dis Sci 2019; 64 (10) 3013-3019
    CrossrefPubMedGoogle Scholar
  • 6 Oura K, Morishita A, Tani J, Masaki T. Tumor immune microenvironment and immunosuppressive therapy in hepatocellular carcinoma: a review. Int J Mol Sci 2021; 22 (11) 5801
    CrossrefPubMedGoogle Scholar
  • 7 Finn RS, Ikeda M, Zhu AX. et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2020; 38 (26) 2960-2970
    CrossrefPubMedGoogle Scholar
  • 8 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol 2018; 7: 17
    CrossrefPubMedGoogle Scholar
  • 9 Yau T, Kang Y-K, Kim T-Y. et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 2020; 6 (11) e204564-e204564
    CrossrefPubMedGoogle Scholar
  • 10 Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010; 195 (02) 281-289
    CrossrefPubMedGoogle Scholar
  • 11 Borcoman E, Kanjanapan Y, Champiat S. et al. Novel patterns of response under immunotherapy. Ann Oncol 2019; 30 (03) 385-396
    CrossrefPubMedGoogle Scholar
  • 12 Wolchok JD, Hoos A, O'Day S. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15 (23) 7412-7420
    CrossrefPubMedGoogle Scholar
  • 13 Champiat S, Dercle L, Ammari S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017; 23 (08) 1920-1928
    CrossrefPubMedGoogle Scholar
  • 14 Alborelli I, Leonards K, Rothschild SI. et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. J Pathol 2020; 250 (01) 19-29
    CrossrefPubMedGoogle Scholar
  • 15 Chan TA, Yarchoan M, Jaffee E. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 2019; 30 (01) 44-56
    CrossrefPubMedGoogle Scholar
  • 16 Fujimoto A. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Ann Oncol 2017; 28: ix31
    CrossrefPubMedGoogle Scholar
  • 17 Ang C, Klempner SJ, Ali SM. et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget 2019; 10 (40) 4018-4025
    CrossrefPubMedGoogle Scholar
  • 18 Liu Z, Ning F, Cai Y. et al. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells. Cancer Commun (Lond) 2021; 41 (01) 62-78
    CrossrefPubMedGoogle Scholar
  • 19 Bassaganyas L, Pinyol R, Esteban-Fabró R. et al. Copy-number alteration burden differentially impacts immune profiles and molecular features of hepatocellular carcinoma. Clin Cancer Res 2020; 26 (23) 6350-6361
    CrossrefPubMedGoogle Scholar
  • 20 Gettinger S, Choi J, Hastings K. et al. Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung CancerAntigen-processing defects and resistance to PD-1 blockade. Cancer Discov 2017; 7 (12) 1420-1435
    CrossrefPubMedGoogle Scholar
  • 21 Zaretsky JM, Garcia-Diaz A, Shin DS. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375 (09) 819-829
    CrossrefPubMedGoogle Scholar
  • 22 Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13 (01) 11-26
    CrossrefPubMedGoogle Scholar
  • 23 Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P. et al. β-catenin activation promotes immune escape and resistance to anti–PD-1 therapy in hepatocellular carcinoma. Cancer Discov 2019; 9 (08) 1124-1141
    CrossrefPubMedGoogle Scholar
  • 24 Kwee SA, Tiirikainen M. Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers. Hepatoma Res 2021; 7: 7
    PubMedGoogle Scholar
  • 25 Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities. Front Oncol 2022; 12: 958720
    CrossrefPubMedGoogle Scholar
  • 26 Harding JJ, Nandakumar S, Armenia J. et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res 2019; 25 (07) 2116-2126
    CrossrefPubMedGoogle Scholar
  • 27 Matsuda A, Ishiguro K, Yan IK, Patel T. Extracellular vesicle-based therapeutic targeting of β-catenin to modulate anticancer immune responses in hepatocellular cancer. Hepatol Commun 2019; 3 (04) 525-541
    CrossrefPubMedGoogle Scholar
  • 28 Kwan V, Unda BK, Singh KK. Wnt signaling networks in autism spectrum disorder and intellectual disability. J Neurodev Disord 2016; 8: 45
    CrossrefPubMedGoogle Scholar
  • 29 Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol 2020; 20 (01) 25-39
    CrossrefPubMedGoogle Scholar
  • 30 Liu J, Fan L, Yu H. et al. Endoplasmic reticulum stress causes liver cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. Hepatology 2019; 70 (01) 241-258
    CrossrefPubMedGoogle Scholar
  • 31 Li N, Wang J, Zhang N. et al. Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother 2018; 67 (02) 271-283
    CrossrefPubMedGoogle Scholar
  • 32 Gao J, Shi LZ, Zhao H. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 2016; 167 (02) 397.e9-404.e9
    PubMedGoogle Scholar
  • 33 Tao S, Liang S, Zeng T, Yin D. Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition. Front Immunol 2023; 13: 1043667
    CrossrefPubMedGoogle Scholar
  • 34 Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015; 12 (12) 681-700
    CrossrefPubMedGoogle Scholar
  • 35 Zheng C, Zheng L, Yoo J-K. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017; 169 (07) 1342.e16-1356.e16
    CrossrefPubMedGoogle Scholar
  • 36 Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet 2018; 14 (06) e1007362
    CrossrefPubMedGoogle Scholar
  • 37 Lai SC, Su YT, Chi CC. et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 2019; 38 (01) 474
    CrossrefPubMedGoogle Scholar
  • 38 Shi R, Zhao H, Zhao S, Yuan H. Molecular subtypes, prognostic and immunotherapeutic relevant gene signatures mediated by DNA methylation regulators in hepatocellular carcinoma. Aging (Albany NY) 2022; 14 (12) 5271-5291
    CrossrefPubMedGoogle Scholar
  • 39 Wang X, Chen M, Liang X. et al. RNF135 promoter methylation is associated with immune infiltration and prognosis in hepatocellular carcinoma. Front Oncol 2022; 11: 752511
    CrossrefPubMedGoogle Scholar
  • 40 Lin Y, Yao Y, Wang Y, Wang L, Cui H. PD-L1 and immune infiltration of m6A RNA methylation regulators and its miRNA regulators in hepatocellular carcinoma. BioMed Res Int 2021; 5516100
    PubMedGoogle Scholar
  • 41 Xu Y, He X, Deng J. et al. Comprehensive analysis of the immune infiltrates and PD-L1 of m6A RNA methylation regulators in hepatocellular carcinoma. Front Cell Dev Biol 2021; 9: 681745
    CrossrefPubMedGoogle Scholar
  • 42 Liu J, Liu Y, Meng L, Liu K, Ji B. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. Oncol Rep 2017; 38 (02) 899-907
    CrossrefPubMedGoogle Scholar
  • 43 Tian Y, Wong VW, Wong GL. et al. Histone deacetylase HDAC8 promotes insulin resistance and β-catenin activation in NAFLD-associated hepatocellular carcinoma. Cancer Res 2015; 75 (22) 4803-4816
    CrossrefPubMedGoogle Scholar
  • 44 Yang W, Feng Y, Zhou J. et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Sci Transl Med 2021; 13 (588) 13
    CrossrefPubMedGoogle Scholar
  • 45 Yang B, Feng X, Liu H. et al. High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma. Oncogene 2020; 39 (42) 6529-6543
    CrossrefPubMedGoogle Scholar
  • 46 Li D, Sun FF, Wang D. et al. Programmed death ligand-1 (PD-L1) regulated by NRF-2/MicroRNA-1 regulatory axis enhances drug resistance and promotes tumorigenic properties in sorafenib-resistant hepatoma cells. Oncol Res 2020; 28 (05) 467-481
    CrossrefPubMedGoogle Scholar
  • 47 Zhang J, Zhao X, Ma X, Yuan Z, Hu M. KCNQ1OT1 contributes to sorafenib resistance and programmed death–ligand–1–mediated immune escape via sponging miR–506 in hepatocellular carcinoma cells. Int J Mol Med 2020; 46 (05) 1794-1804
    PubMedGoogle Scholar
  • 48 Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 2021; 184 (21) 5309-5337
    CrossrefPubMedGoogle Scholar
  • 49 Harkus U, Wankell M, Palamuthusingam P. et al. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Semin Cancer Biol 2022; 86: 799-815
    CrossrefPubMedGoogle Scholar
  • 50 Fu J, Xu D, Liu Z. et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132 (07) 2328-2339
    CrossrefPubMedGoogle Scholar
  • 51 Langhans B, Nischalke HD, Krämer B. et al. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother 2019; 68 (12) 2055-2066
    CrossrefPubMedGoogle Scholar
  • 52 Sun L, Xu G, Liao W. et al. Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis. Oncotarget 2017; 8 (24) 39658-39672
    CrossrefPubMedGoogle Scholar
  • 53 Zhao C, Pang X, Yang Z, Wang S, Deng H, Chen X. Nanomaterials targeting tumor associated macrophages for cancer immunotherapy. J Control Release 2022; 341: 272-284
    CrossrefPubMedGoogle Scholar
  • 54 Wang Z, Wang Y, Gao P, Ding J. Immune checkpoint inhibitor resistance in hepatocellular carcinoma. Cancer Lett 2023; 555: 216038
    CrossrefPubMedGoogle Scholar
  • 55 Tomiyama T, Itoh S, Iseda N. et al. Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma. Oncol Lett 2022; 23 (03) 93
    CrossrefPubMedGoogle Scholar
  • 56 Kryczek I, Liu R, Wang G. et al. FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 2009; 69 (09) 3995-4000
    CrossrefPubMedGoogle Scholar
  • 57 Chen Y, Liu Z, Liang S. et al. Role of Kupffer cells in the induction of tolerance of orthotopic liver transplantation in rats. Liver Transpl 2008; 14 (06) 823-836
    CrossrefPubMedGoogle Scholar
  • 58 Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69 (20) 8067-8075
    CrossrefPubMedGoogle Scholar
  • 59 Marin JJG, Macias RIR, Monte MJ. et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers (Basel) 2020; 12 (06) 12
    CrossrefPubMedGoogle Scholar
  • 60 Chan LC, Li CW, Xia W. et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 2019; 129 (08) 3324-3338
    CrossrefPubMedGoogle Scholar
  • 61 Horst AK, Neumann K, Diehl L, Tiegs G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol Immunol 2016; 13 (03) 277-292
    CrossrefPubMedGoogle Scholar
  • 62 Tan W, Luo X, Li W. et al. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma. EBioMedicine 2019; 40: 446-456
    CrossrefPubMedGoogle Scholar
  • 63 Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity 2019; 50 (04) 924-940
    CrossrefPubMedGoogle Scholar
  • 64 Capece D, Fischietti M, Verzella D. et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Res Int 2013; 187204
    PubMedGoogle Scholar
  • 65 Ungerleider N, Han C, Zhang J, Yao L, Wu T. TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells. Mol Carcinog 2017; 56 (04) 1302-1311
    CrossrefPubMedGoogle Scholar
  • 66 Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?. Am Soc Clin Oncol Educ Book 2019; 39: 147-164
    CrossrefPubMedGoogle Scholar
  • 67 Xu M, Chang Y, Zhu G, Zhu X, Song X, Li J. Transforming cold tumors into hot ones with a metal-organic framework-based biomimetic nanosystem for enhanced immunotherapy. ACS Appl Mater Interfaces 2023; 15 (14) 17470-17484
    CrossrefPubMedGoogle Scholar
  • 68 Lu JC, Zhang PF, Huang XY. et al. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. J Hematol Oncol 2021; 14 (01) 200
    CrossrefPubMedGoogle Scholar
  • 69 Kaiser M, Semeraro MD, Herrmann M, Absenger G, Gerger A, Renner W. Immune aging and immunotherapy in cancer. Int J Mol Sci 2021; 22 (13) 7016
    CrossrefPubMedGoogle Scholar
  • 70 Ye J, Peng G. Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy. OncoImmunology 2015; 4 (03) e994398
    CrossrefPubMedGoogle Scholar
  • 71 Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy. Front Immunol 2020; 10: 2989
    CrossrefPubMedGoogle Scholar
  • 72 Qi X, Liu Y, Hussein S. et al. The species of gut bacteria associated with antitumor immunity in cancer therapy. Cells 2022; 11 (22) 11
    CrossrefPubMedGoogle Scholar
  • 73 Zheng Y, Wang T, Tu X. et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 2019; 7 (01) 193
    CrossrefPubMedGoogle Scholar
  • 74 Zheng Y, Tian X, Wang T. et al. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Mol Cancer 2019; 18 (01) 61
    CrossrefPubMedGoogle Scholar
  • 75 Gedaly R, Angulo P, Hundley J. et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30 (12) 4951-4958
    PubMedGoogle Scholar
  • 76 Wan X, Cheng C, Lin Z. et al. The attenuated hepatocellular carcinoma-specific Listeria vaccine Lmdd-MPFG prevents tumor occurrence through immune regulation of dendritic cells. Oncotarget 2015; 6 (11) 8822-8838
    CrossrefPubMedGoogle Scholar
  • 77 Friedman RS, Frankel FR, Xu Z, Lieberman J. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Virol 2000; 74 (21) 9987-9993
    CrossrefPubMedGoogle Scholar
  • 78 Holmgaard RB, Schaer DA, Li Y. et al. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer 2018; 6 (01) 47
    CrossrefPubMedGoogle Scholar
  • 79 Kato Y, Bao X, Macgrath S. et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol 2016; 27: vi1
    CrossrefPubMedGoogle Scholar
  • 80 Wei CY, Zhu MX, Zhang PF. et al. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol 2022; 77 (01) 163-176
    CrossrefPubMedGoogle Scholar
  • 81 Duffy AG, Ulahannan SV, Makorova-Rusher O. et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017; 66 (03) 545-551
    CrossrefPubMedGoogle Scholar
  • 82 Fessas P, Scheiner B, D'Alessio A. et al. PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. Future Oncol 2023; 19 (07) 499-507
    CrossrefPubMedGoogle Scholar
  • 83 Tanoue T, Morita S, Plichta DR. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 2019; 565 (7741) 600-605
    CrossrefPubMedGoogle Scholar
  • 84 [Anonymous] Phase A. Updated survival and secondary safety and efficacy analyses from CA 209-678: a phase 2, open-label, single-center study of Y90-radioembolization in combination with nivolumab in asian patients with advanced hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2021; 17 (11, Suppl 6): 18-19
    PubMedGoogle Scholar
  • 85 Deng L, Sun J, Chen X, Liu L, Wu D. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma. J Exp Clin Cancer Res 2019; 38 (01) 316
    CrossrefPubMedGoogle Scholar
  • 86 Deldar Abad Paskeh M, Mirzaei S, Ashrafizadeh M, Zarrabi A, Sethi G. Wnt/β-catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathways. J Hepatocell Carcinoma 2021; 8: 1415-1444
    CrossrefPubMedGoogle Scholar
  • 87 Akula SM, Abrams SL, Steelman LS. et al. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opin Ther Targets 2019; 23 (11) 915-929
    CrossrefPubMedGoogle Scholar
  • 88 Fulgenzi CAM, D'Alessio A, Ogunbiyi O. et al. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?. Expert Opin Investig Drugs 2022; 31 (07) 681-691
    CrossrefPubMedGoogle Scholar
  • 89 Cossío FP, Esteller M, Berdasco M. Towards a more precise therapy in cancer: exploring epigenetic complexity. Curr Opin Chem Biol 2020; 57: 41-49
    CrossrefPubMedGoogle Scholar
  • 90 Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother 2016; 65 (07) 787-796
    CrossrefPubMedGoogle Scholar
  • 91 Zhu S, Denman CJ, Cobanoglu ZS. et al. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Pharm Res 2015; 32 (03) 779-792
    CrossrefPubMedGoogle Scholar
  • 92 Costantini B, Kordasti SY, Kulasekararaj AG. et al. The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome. Haematologica 2013; 98 (08) 1196-1205
    CrossrefPubMedGoogle Scholar
  • 93 Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD. Epigenetic therapy in immune-oncology. Nat Rev Cancer 2019; 19 (03) 151-161
    CrossrefPubMedGoogle Scholar
  • 94 Jueliger S, Lyons J, Cannito S. et al. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics 2016; 11 (10) 709-720
    CrossrefPubMedGoogle Scholar
  • 95 Llopiz D, Ruiz M, Villanueva L. et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 2019; 68 (03) 379-393
    CrossrefPubMedGoogle Scholar
  • 96 Cheng WY, Wu CY, Yu J. The role of gut microbiota in cancer treatment: friend or foe?. Gut 2020; 69 (10) 1867-1876
    CrossrefPubMedGoogle Scholar
  • 97 Pandya G, Kirtonia A, Singh A. et al. A comprehensive review of the multifaceted role of the microbiota in human pancreatic carcinoma. Semin Cancer Biol 2022; 86 (Pt 3): 682-692
    CrossrefPubMedGoogle Scholar
  • 98 Lu Y, Yuan X, Wang M. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol 2022; 15 (01) 47
    CrossrefPubMedGoogle Scholar
  • 99 Ma C, Han M, Heinrich B. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 2018; 360 (6391) 360
    PubMedGoogle Scholar
  • 100 Fessas P, Naeem M, Pinter M. et al. Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. Liver Cancer 2021; 10 (06) 583-592
    CrossrefPubMedGoogle Scholar
  • 101 Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015; 523 (7559) 231-235
    CrossrefPubMedGoogle Scholar
  • 102 Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 2014; 20 (04) 265-271
    CrossrefPubMedGoogle Scholar
  • 103 Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008; 8: 1
    PubMedGoogle Scholar
  • 104 Wolter P, Beuselinck B, Pans S, Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009; 48 (04) 621-624
    CrossrefPubMedGoogle Scholar
  • 105 Di Giacomo AM, Danielli R, Guidoboni M. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 2009; 58 (08) 1297-1306
    CrossrefPubMedGoogle Scholar
  • 106 Kim JY, Park JE, Jo Y. et al. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients. Neuro-oncol 2019; 21 (03) 404-414
    CrossrefPubMedGoogle Scholar
  • 107 Grierson P, Crites D, Ruzinova MB, Yano M, Lim KH. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: a case report of late response after pseudoprogression. Hepatol Commun 2017; 2 (02) 148-151
    CrossrefPubMedGoogle Scholar
  • 108 Watanabe Y, Ogawa M, Tamura Y. et al. A case of pseudoprogression in hepatocellular carcinoma treated with atezolizumab plus bevacizumab. J Investig Med High Impact Case Rep 2021 ;9:23247096211058489
    PubMedGoogle Scholar
  • 109 Mamdani H, Wu H, O'Neil BH, Sehdev A. Excellent response to Anti-PD-1 therapy in a patient with hepatocellular carcinoma: case report and review of literature. Discov Med 2017; 23 (128) 331-336
    PubMedGoogle Scholar
  • 110 Qin S, Ren Z, Meng Z, Chen Z, Chai X. Effectiveness of anti-PD-1 for hepatocellular carcinoma - authors' reply. Lancet Oncol 2020; 21 (06) e294
    CrossrefPubMedGoogle Scholar
  • 111 Rimola J, Da Fonseca LG, Sapena V. et al. Radiological response to nivolumab in patients with hepatocellular carcinoma: a multicenter analysis of real-life practice. Eur J Radiol 2021; 135: 109484
    CrossrefPubMedGoogle Scholar
  • 112 Lewis S, Cedillo MA, Lee KM. et al. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC. Abdom Radiol (NY) 2022; 47 (03) 969-980
    CrossrefPubMedGoogle Scholar
  • 113 Lee DH, Hwang S, Koh YH. et al. Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST?. Front Med (Lausanne) 2021; 8: 771887
    CrossrefPubMedGoogle Scholar
  • 114 Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. BioDrugs 2020; 34 (04) 463-476
    CrossrefPubMedGoogle Scholar
  • 115 Tanizaki J, Hayashi H, Kimura M. et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer 2016; 102: 44-48
    CrossrefPubMedGoogle Scholar
  • 116 Li Q, Dong Y, Pan Y, Tang H, Li D. Case report: clinical responses to tislelizumab as a first-line therapy for primary hepatocellular carcinoma with B-cell indolent lymphoma. Front Immunol 2021; 12: 634559
    CrossrefPubMedGoogle Scholar
  • 117 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021; 18 (08) 525-543
    CrossrefPubMedGoogle Scholar
  • 118 Hu X, Chen R, Wei Q, Xu X. The Landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?. Int J Biol Sci 2022; 18 (02) 536-551
    CrossrefPubMedGoogle Scholar
  • 119 Spahn S, Roessler D, Pompilia R. et al. Clinical and genetic tumor characteristics of responding and non-responding patients to PD-1 inhibition in hepatocellular carcinoma. Cancers (Basel) 2020; 12 (12) 3830
    CrossrefPubMedGoogle Scholar
  • 120 Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T. Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. FEBS J 2006; 273 (16) 3837-3849
    CrossrefPubMedGoogle Scholar
  • 121 Li M-S, Li P-F, He S-P, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol 2002; 8 (03) 469-475
    CrossrefPubMedGoogle Scholar
  • 122 Lin B, Zhu M, Wang W. et al. Structural basis for alpha fetoprotein-mediated inhibition of caspase-3 activity in hepatocellular carcinoma cells. Int J Cancer 2017; 141 (07) 1413-1421
    CrossrefPubMedGoogle Scholar
  • 123 Rapposelli IG, De Matteis S, Lanuti P. et al. Heterogeneity of response and immune system activity during treatment with nivolumab in hepatocellular carcinoma: results from a single-institution retrospective analysis. Cancers (Basel) 2021; 13 (02) 213
    CrossrefPubMedGoogle Scholar
  • 124 Berghoff AS, Preusser M. New developments in brain metastases. Ther Adv Neurol Disord 2018; 11: 1756286418785502
    CrossrefPubMedGoogle Scholar
  • 125 Urban H, Steidl E, Hattingen E. et al. Immune checkpoint inhibitor-induced cerebral pseudoprogression: patterns and categorization. Front Immunol 2022; 12: 798811
    CrossrefPubMedGoogle Scholar
  • 126 Yoshida M, Ogino H, Iwata H. et al. Transient increases of serum AFP and PIVKA-II levels after proton therapy do not necessarily indicate progression of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2017; 99: E202-E203
    CrossrefPubMedGoogle Scholar
  • 127 Godfrey D, Vernuccio F, Stephens S. et al. Evaluation of post-stereotactic body radiation therapy response assessment for hepatocellular carcinoma: an appraisal of RECIST, m-RECIST and WHO criteria. Int J Radiat Oncol Biol Phys 2018; 102: e53
    CrossrefPubMedGoogle Scholar
  • 128 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedGoogle Scholar
  • 129 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021; 75 (04) 960-974
    CrossrefPubMedGoogle Scholar
  • 130 Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19 (14) 3936-3943
    CrossrefPubMedGoogle Scholar
  • 131 Decazes P, Bohn P. Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications. Cancers (Basel) 2020; 12 (02) 371
    CrossrefPubMedGoogle Scholar
  • 132 Iyalomhe O, Farwell MD. Immune PET imaging. Radiol Clin North Am 2021; 59 (05) 875-886
    CrossrefPubMedGoogle Scholar
  • 133 Wang J, Wang X, Yang X, Zhao H, Huo L. FDG PET findings of hyperprogression during immunotherapy in a patient with hepatocellular carcinoma. Clin Nucl Med 2020; 45 (01) 92-93
    CrossrefPubMedGoogle Scholar
  • 134 Fuentes-Antrás J, Provencio M, Díaz-Rubio E. Hyperprogression as a distinct outcome after immunotherapy. Cancer Treat Rev 2018; 70: 16-21
    CrossrefPubMedGoogle Scholar
  • 135 Lo Russo G, Facchinetti F, Tiseo M, Garassino MC, Ferrara R. Hyperprogressive disease upon immune checkpoint blockade: focus on non-small cell lung cancer. Curr Oncol Rep 2020; 22 (05) 41
    CrossrefPubMedGoogle Scholar
  • 136 Wong DJ, Lee J, Choo SP, Thng CH, Hennedige T. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy 2019; 11 (03) 167-175
    CrossrefPubMedGoogle Scholar
  • 137 Kim CG, Kim C, Yoon SE. et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol 2021; 74 (02) 350-359
    CrossrefPubMedGoogle Scholar
  • 138 Singh B, Kaur P, Maroules M. Hyperprogression in a patient with hepatocellular cancer treated with atezolizumab and bevacizumab: a case report and review of literature. J Investig Med High Impact Case Rep 2021; 9: 2324709621992207
    PubMedGoogle Scholar
  • 139 Zhang L, Wu L, Chen Q. et al. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2020; 31: 100673
    CrossrefPubMedGoogle Scholar
  • 140 Maesaka K, Sakamori R, Yamada R. et al. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy. Hepatol Res 2022; 52 (03) 298-307
    CrossrefPubMedGoogle Scholar
  • 141 Scheiner B, Kirstein MM, Hucke F. et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019; 49 (10) 1323-1333
    CrossrefPubMedGoogle Scholar
  • 142 Choi WM, Kim JY, Choi J. et al. Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver Int 2021; 41 (09) 2189-2199
    CrossrefPubMedGoogle Scholar
  • 143 Lo Russo G, Moro M, Sommariva M. et al. Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 2019; 25 (03) 989-999
    CrossrefPubMedGoogle Scholar
  • 144 Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol 2023; 8 (08) 760-770
    CrossrefPubMedGoogle Scholar
  • 145 Chen L, Gibbons DL, Goswami S. et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5: 5241
    CrossrefPubMedGoogle Scholar
  • 146 Dong H, Strome SE, Salomao DR. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8 (08) 793-800
    CrossrefPubMedGoogle Scholar
  • 147 Johnson DB, Nixon MJ, Wang Y. et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight 2018; 3 (24) 3
    CrossrefPubMedGoogle Scholar
  • 148 Chan SL. Hyperprogression in hepatocellular carcinoma: Illusion or reality?. J Hepatol 2021; 74 (02) 269-271
    CrossrefPubMedGoogle Scholar
  • 149 Dulos J, Carven GJ, van Boxtel SJ. et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 2012; 35 (02) 169-178
    CrossrefPubMedGoogle Scholar
  • 150 Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci 2017; 19 (01) 19
    CrossrefPubMedGoogle Scholar
  • 151 Mei J, Li MQ, Ding D. et al. Indoleamine 2,3-dioxygenase-1 (IDO1) enhances survival and invasiveness of endometrial stromal cells via the activation of JNK signaling pathway. Int J Clin Exp Pathol 2013; 6 (03) 431-444
    PubMedGoogle Scholar
  • 152 Tang D, Yue L, Yao R. et al. P53 prevent tumor invasion and metastasis by down-regulating IDO in lung cancer. Oncotarget 2017; 8 (33) 54548-54557
    CrossrefPubMedGoogle Scholar
  • 153 Wei C, Yi C, Qing H. et al. 998P The biomarkers associated with hyperprogression (HP) to immune checkpoint inhibitors (ICIs) in Chinese hepatocellular carcinoma (HCC) patients. Ann Oncol 2020; 31: S695
    CrossrefPubMedGoogle Scholar
  • 154 Champiat S, Besse B, Marabelle A. Hyperprogression during immunotherapy: do we really want to know?. Ann Oncol 2019; 30 (07) 1028-1031
    CrossrefPubMedGoogle Scholar
  • 155 Liu J, Wu Q, Wu S, Xie X. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs). Clin Transl Oncol 2021; 23 (09) 1782-1793
    CrossrefPubMedGoogle Scholar
  • 156 Lin M, Vanneste BGL, Yu Q, Chen Z, Peng J, Cai X. Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. Transl Lung Cancer Res 2021; 10 (07) 3276-3291
    CrossrefPubMedGoogle Scholar
  • 157 Adashek JJ, Subbiah IM, Matos I. et al. Hyperprogression and immunotherapy: fact, fiction, or alternative fact?. Trends Cancer 2020; 6 (03) 181-191
    CrossrefPubMedGoogle Scholar
  • 158 Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012; 24 (05) 331-341
    CrossrefPubMedGoogle Scholar
  • 159 Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol 2013; 14 (05) 428-436
    CrossrefPubMedGoogle Scholar
  • 160 Hakim FT, Flomerfelt FA, Boyiadzis M, Gress RE. Aging, immunity and cancer. Curr Opin Immunol 2004; 16 (02) 151-156
    CrossrefPubMedGoogle Scholar
  • 161 Fülöp T, Larbi A, Pawelec G. Human T cell aging and the impact of persistent viral infections. Front Immunol 2013; 4: 271
    CrossrefPubMedGoogle Scholar
  • 162 Saâda-Bouzid E, Defaucheux C, Karabajakian A. et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017; 28 (07) 1605-1611
    CrossrefPubMedGoogle Scholar
  • 163 Wei Z, Zhang Y. Immune cells in hyperprogressive disease under immune checkpoint-based immunotherapy. Cells 2022; 11 (11) 11
    CrossrefPubMedGoogle Scholar
  • 164 Wei X, Jiang Y, Zhang X. et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol 2019; 37 (24) 2141-2151
    CrossrefPubMedGoogle Scholar
  • 165 Kim PH, Choi SH, Kim JH, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol 2019; 20 (03) 385-398
    CrossrefPubMedGoogle Scholar
  • 166 Sieghart W, Hucke F, Pinter M. et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013; 57 (06) 2261-2273
    CrossrefPubMedGoogle Scholar
  • 167 Adhoute X, Penaranda G, Naude S. et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol 2015; 62 (04) 855-862
    CrossrefPubMedGoogle Scholar
  • 168 Okajima C, Arii S, Tanaka S. et al. Prognostic role of Child-Pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg 2015; 209 (01) 199-205
    CrossrefPubMedGoogle Scholar
  • 169 Hung HH, Chao Y, Chiou YY. et al. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014; 93 (29) e348
    CrossrefPubMedGoogle Scholar
  • 170 Cui H, Dai G, Guan J. Programmed cell death protein-1 (PD-1)-targeted immunotherapy for advanced hepatocellular carcinoma in real world. OncoTargets Ther 2020; 13: 143-149
    CrossrefPubMedGoogle Scholar
  • 171 Floridi C, Pesapane F, Angileri SA. et al. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017; 34 (10) 174
    CrossrefPubMedGoogle Scholar
  • 172 Casadei Gardini A, Scarpi E, Faloppi L. et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget 2016; 7 (41) 67142-67149
    CrossrefPubMedGoogle Scholar